Photo of Marc M. Loriaux, M.D., Ph.D.

Marc M. Loriaux M.D., Ph.D.

Marc Loriaux, M.D., Ph.D. joined the Department of Pathology and Medicine in July, 2003 after completing a fellowship in hematopathology at OHSU. He will help to staff the diagnostic hematopathology service and continue his research in Dr. Brian Druker’s laboratory studying tyrosine kinases as possible therapeutic targets in the treatment of hematologic malignancies.

Education

  • B.A., University of Colorado, Boulder Colorado 1987
  • M.D., Oregon Health & Science University, Portland Oregon 1997
  • Ph.D., Oregon Health & Science University, Portland Oregon 1995
  • Residency:

    • Anatomic and Clinical Pathology, Oregon Health & Science University, Portland, Oregon, 1997-2001
  • Fellowship:

    • Hematopathology, Oregon Health & Science University, Portland, Oregon, 2001-2003
  • Certifications:

    • Anatomic and Clinical Pathology, American Board of Pathology, 2002

Publications

  • "CPX-351 exhibits potent and direct ex vivo cytotoxicity against AML blasts with enhanced efficacy for cells harboring the FLT3-ITD mutation." Leukemia Research In: , Vol. 53, 01.02.2017, p. 39-49.
  • "Targeting BCL-2 and ABL/LYN in Philadelphia chromosome-positive acute lymphoblastic leukemia." Science Translational Medicine In: , Vol. 8, No. 354, 354ra114, 31.08.2016.
  • "Alterations in acute myeloid leukaemia bone marrow stromal cell exosome content coincide with gains in tyrosine kinase inhibitor resistance." British Journal of Haematology  In: , Vol. 172, No. 6, 01.03.2016, p. 983-986.
  • "The colony-Stimulating factor 3 receptor T640N mutation is oncogenic, sensitive toJAKInhibition, and mimics T618i." Clinical Cancer Research In: , Vol. 22, No. 3, 01.02.2016, p. 757-764.
  • "Coordinate regulation of residual bone marrow function by paracrine trafficking of AML exosomes." Leukemia In: , 25.06.2015.
  • "Therapeutically targetable ALK mutations in leukemia." Cancer Research In: , Vol. 75, No. 11, 01.06.2015, p. 2146-2150.
  • "YM155 potently kills acute lymphoblastic leukemia cells through activation of the DNA damage pathway." Journal of Hematology and Oncology In: , Vol. 8, No. 1, 39, 22.04.2015.
  • "Disruption of IKAROS activity in primitive chronic-phase CML cells mimics myeloid disease progression." Blood In: , Vol. 125, No. 3, 15.01.2015, p. 504-515.
  • "Small molecule inhibitor screen identifies synergistic activity of the bromodomain inhibitor CPI203 and bortezomib in drug resistant myeloma." Oncotarget In: , Vol. 6, No. 22, 2015, p. 18921-18932.
  • "BCR-ABL1 promotes leukemia by converting p27 into a cytoplasmic oncoprotein." Blood In: , Vol. 124, No. 22, 20.11.2014, p. 3260-3273.
  • "A potential therapeutic strategy for chronic lymphocytic leukemia by combining idelalisib and GS-9973, a novel spleen tyrosine kinase (Syk) inhibitor." Oncotarget In: , Vol. 5, No. 4, 2014, p. 908-915.
  • "Comparison of methods to identify aberrant expression patterns in individual patients : Augmenting our toolkit for precision medicine." Genome Medicine  In: , Vol. 5, No. 11, 103, 29.11.2013.
  • "The CSF3R T618I mutation causes a lethal neutrophilic neoplasia in Mice that is responsive to therapeutic JAK inhibition." Blood In: , Vol. 122, No. 22, 21.11.2013, p. 3628-3631.
  • "CX-4945, a selective inhibitor of casein kinase-2 (CK2), exhibits anti-tumor activity in hematologic malignancies including enhanced activity in chronic lymphocytic leukemia when combined with fludarabine and inhibitors of the B-cell receptor pathway." Leukemia In: , Vol. 27, No. 10, 10.2013, p. 2094-2096.
  • "A case study of personalized therapy for osteosarcoma." Pediatric Blood and Cancer  In: , Vol. 60, No. 8, 08.2013, p. 1313-1319.
  • "Imatinib and dasatinib inhibit hemangiosarcoma and implicate PDGFR-β and Src in tumor growth." Translational Oncology In: , Vol. 6, No. 2, 04.2013, p. 158-168.
  • "HitWalker : Variant prioritization for personalized functional cancer genomics." Bioinformatics In: , Vol. 29, No. 4, 15.02.2013, p. 509-510.
  • "The selective syk inhibitor P505-15 (PRT062607) inhibits B cell signaling and function in vitro and in vivo and augments the activity of fludarabine in chronic lymphocytic leukemias." Journal of Pharmacology and Experimental Therapeutics In: , Vol. 344, No. 2, 02.2013, p. 378-387.
  • "Kinase pathway dependence in primary human leukemias determined by rapid inhibitor screening." Cancer Research In: , Vol. 73, No. 1, 01.01.2013, p. 285-296.
  • "Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML." New England Journal of Medicine In: , Vol. 368, No. 19, 2013, p. 1781-1790.
  • "Multiplex high-throughput gene mutation analysis in acute myeloid leukemia." Human Pathology  In: , Vol. 43, No. 12, 12.2012, p. 2167-2176.
  • "Crosstalk between ROR1 and the Pre-B Cell Receptor Promotes Survival of t(1;19) Acute Lymphoblastic Leukemia." Cancer Cell In: , Vol. 22, No. 5, 13.11.2012, p. 656-667.
  • "An adaptive Src-PDGFRA-Raf axis in rhabdomyosarcoma." Biochemical and Biophysical Research Communications  In: , Vol. 426, No. 3, 28.09.2012, p. 363-368.
  • "Effects of plerixafor in combination with BCR-ABL kinase inhibition in a murine model of CML." Blood In: , Vol. 120, No. 13, 27.09.2012, p. 2658-2668.
  • "In vitro sensitivity to dasatinib in lymphoblasts from a patient with t(17;19)(q22;p13) gene rearrangement pre-B acute lymphoblastic leukemia." Pediatric Blood and Cancer In: , Vol. 59, No. 3, 09.2012, p. 576-579.
  • "Newly described activating JAK3 mutations in T-cell acute lymphoblastic leukemia." Leukemia In: , Vol. 26, No. 9, 09.2012, p. 2144-2146.
  • "Creation of fibrinogen-enhanced experimental blood clots to evaluate mechanical thrombectomy devices for treatment of acute stroke : An in vitro study." Journal of Vascular and Interventional Radiology  In: , Vol. 23, No. 8, 08.2012, p. 1077-1083.
  • "TSLP signaling network revealed by SILAC-based phosphoproteomics." Molecular & cellular proteomics : MCP  In: , Vol. 11, No. 6, 06.2012.
  • "TNFα facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms." Blood In: , Vol. 118, No. 24, 08.12.2011, p. 6392-6398.
  • "Potent activity of ponatinib (AP24534) in models of FLT3-driven acute myeloid leukemia and other hematologic malignancies." Molecular Cancer Therapeutics In: , Vol. 10, No. 6, 06.2011, p. 1028-1035.

Additional information

Edit profile